By Sabela Ojea
Tempest Therapeutics is exploring strategic alternatives for the business, including mergers, partnerships, acquisition, joint ventures and licensing agreements.
Shares rose 9.2% to $7.81 in post-market trading. Through Wednesday's close, the stock has fallen 85% over the past 12 months.
The clinical-stage biotechnology company on Wednesday said that it hired MTS Health Partners as financial adviser for its strategic evaluation process.
"Given the positive data and commercial potential with this [company] pipeline, as well as the clearance from the Food and Drug Administration on the lead program's pivotal study, we believe this is a rare opportunity for a partner," Chief Executive Stephen Brady said.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
April 09, 2025 17:01 ET (21:01 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。